Quent Capital LLC Sells 49 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Quent Capital LLC cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.1% during the 4th quarter, Holdings Channel reports. The firm owned 491 shares of the pharmaceutical company’s stock after selling 49 shares during the period. Quent Capital LLC’s holdings in Vertex Pharmaceuticals were worth $198,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of VRTX. Creative Planning boosted its position in Vertex Pharmaceuticals by 1.7% during the 3rd quarter. Creative Planning now owns 80,467 shares of the pharmaceutical company’s stock valued at $37,424,000 after acquiring an additional 1,350 shares in the last quarter. Occidental Asset Management LLC boosted its position in Vertex Pharmaceuticals by 51.7% during the 3rd quarter. Occidental Asset Management LLC now owns 695 shares of the pharmaceutical company’s stock valued at $323,000 after acquiring an additional 237 shares in the last quarter. NBC Securities Inc. boosted its position in Vertex Pharmaceuticals by 34.5% during the 3rd quarter. NBC Securities Inc. now owns 160 shares of the pharmaceutical company’s stock valued at $74,000 after acquiring an additional 41 shares in the last quarter. Capital Advisors Wealth Management LLC boosted its position in Vertex Pharmaceuticals by 1.8% during the 3rd quarter. Capital Advisors Wealth Management LLC now owns 1,987 shares of the pharmaceutical company’s stock valued at $924,000 after acquiring an additional 35 shares in the last quarter. Finally, MN Wealth Advisors LLC boosted its position in Vertex Pharmaceuticals by 2.4% during the 3rd quarter. MN Wealth Advisors LLC now owns 2,728 shares of the pharmaceutical company’s stock valued at $1,269,000 after acquiring an additional 65 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Ourania Tatsis sold 310 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total transaction of $142,547.30. Following the completion of the sale, the executive vice president now owns 64,021 shares of the company’s stock, valued at $29,438,776.43. The trade was a 0.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $453.20 on Thursday. The firm has a market cap of $116.71 billion, a PE ratio of -227.74, a P/E/G ratio of 1.80 and a beta of 0.41. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $435.91 and a two-hundred day simple moving average of $461.85. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.94 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on VRTX shares. Truist Financial lifted their price objective on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research report on Tuesday. Piper Sandler dropped their price target on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Finally, Citigroup began coverage on Vertex Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $575.00 price target on the stock. Ten investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $505.96.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.